![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…
Update on the Simplified Tender Offer and Squeeze-out on NHOA
No Conditional Price Supplement PayableTAIPEI, Taiwan--(BUSINESS WIRE)--Reference is made to the simplified…
DoorDash Announces Closing of Upsized $2.75 Billion Offering of 0% Convertible Senior Notes
Opportunistic capital raise with proceeds used to enhance strategic flexibility A portion…